Bayer to invest $30M in lab to create drugs for chronic lung disease

Bayer will invest more than $30 million over the next five years to open a lab in Boston's Brigham and Women's Hospital to develop drugs to treat chronic lung diseases, according to The Boston Globe.

Roughly 20 scientists from Bayer, Brigham and Women's and Boston-based Massachusetts General Hospital will work in the lab, and the three organizations will evenly split the rights to any discoveries made.

Current chronic lung disease treatments only address symptoms and aren't very effective, Edwin Silverman, MD, PhD, a pulmonary specialist at Brigham who will work in the new lab, told The Boston Globe.

Additionally, the World Health Organization predicts chronic obstructive pulmonary disease will be the third leading cause of death globally by 2030.

Dr. Silverman told The Boston Globe he believes the lab will allow them to develop treatments that treat the underlying causes of chronic lung diseases instead of treating only the symptoms.

Read the full report here.

More articles on pharmacy:

World Pharmacist Day promotes use of safe and effective medicines

USP delays release of updated compounding standards

Americans pay up to 67 times more for drugs than other countries

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars